Physician profile
Michael Mikhail
NPI 1043384035
$3,616.70
in general payments reported to CMS, 2019-2025
38 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $473 · 2021: $763 · 2022: $660 · 2023: $56.01 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $479.36 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $410.42 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $366.71 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $323.56 | 2019-2022 | |
| Celgene Corporation | $246.10 | 2019-2020 | |
| Caris Mpi, INC. | $180.38 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Seagen INC. | $138.45 | 2019-2021 | |
| Akcea Therapeutics, INC. | $132.04 | 2019 | |
| Glaxosmithkline, LLC. | $124.74 | 2022 | |
| Janssen Biotech, INC. | $118.53 | 2019-2020 | |
| Genentech USA, INC. | $101.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.29 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $55.44 | 2025 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $51.98 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.61 | 2019 | |
| Amgen INC. | $48.90 | 2019 | |
| Daiichi Sankyo INC. | $45.57 | 2020 | |
| Gilead Sciences, INC. | $43.61 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $42.34 | 2019-2020 | |
| Astellas Pharma US INC | $40.56 | 2019-2023 | Padcev |
| Eisai INC. | $35.88 | 2019-2020 | |
| Emd Serono, INC. | $32.09 | 2019 | |
| Stemline Therapeutics INC. | $31.80 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $31.69 | 2019 | |
| Tesaro, INC. | $30.96 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $29.78 | 2019 | |
| Pfizer INC. | $29.15 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.79 | 2019 | |
| Verastem, INC. | $21.97 | 2019 | |
| Kite Pharma, INC. | $18.25 | 2020 | |
| Mylan Institutional INC. | $17.25 | 2020 | |
| Foundation Medicine, INC. | $16.32 | 2019 | |
| Teleflex LLC | $15.70 | 2022 | |
| Puma Biotechnology, INC. | $14.84 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.18 | 2019 | |
| Taiho Oncology, INC. | $12.85 | 2019 | |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mikhail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.